While it does not directly cause nutrient loss, it often leads people to reduce fiber intake further, which compounds the problem of inadequate nutrition
Tirzepatide, a dual GIP/GLP-1 receptor agonist, is studied in metabolic research
AOD-9604 is the most targeted option for fat metabolism, specifically designed to stimulate lipolysis and inhibit fat cell formation without elevating IGF-1 or disrupting insulin sensitivity, making it a relevant choice given that perimenopausal women already face increased insulin resistance risk
The peptide is found throughout the body and circulates at higher levels in younger tissue, with concentrations that tend to fall with age
You're not just managing symptoms
And sometimes uncomfortable